Undersøgelse af effektivitet og sikkerhed af LNP023 hos deltagere med aktiv lupus nefritis klasse III-IV, +/- V
Et adaptivt, randomiseret, dobbeltblindt, dosisudforskning, parallelgruppe, placebokontrolleret, multicenter fase 2-forsøg til evaluering af effektivitet, sikkerhed og tolerabilitet af LNP023 i kombination med standardbehandling med og uden orale kortikosteroider hos patienter med aktiv lupus Nefritis klasse III-IV, +/- V
The overall purpose of this two-part study is to evaluate the efficacy, safety and tolerability of iptacopan (LNP023) in addition to standard of care treatment.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
The overall purpose of this two-part study is to evaluate the efficacy, safety and tolerability of iptacopan (LNP023) in addition to standard of care treatment.
Undersøgelsestype
Undersøgelsestype
Tilmelding (Faktiske)
Tilmelding
Fase
Fase
- Fase 2
Kontakter og lokationer
Studiesteder
-
-
-
Santa Fe, Argentina, S3000EPV
- Novartis Investigative Site
-
-
-
-
-
Salvador, Brasilien, 40323-010
- Novartis Investigative Site
-
-
Estado de Bahia
-
Salvador, Estado de Bahia, Brasilien, 40150-150
- Novartis Investigative Site
-
-
Minas Gerais
-
Belo Horizonte, Minas Gerais, Brasilien, 30150-221
- Novartis Investigative Site
-
-
São Paulo
-
São Paulo, São Paulo, Brasilien, 05403-000
- Novartis Investigative Site
-
São Paulo, São Paulo, Brasilien, 04038-002
- Novartis Investigative Site
-
-
-
-
-
Montería, Colombia, 230004
- Novartis Investigative Site
-
-
Atlántico
-
Barranquilla, Atlántico, Colombia, 080020
- Novartis Investigative Site
-
-
Cundinamarca
-
Bogota, Cundinamarca, Colombia, 111411
- Novartis Investigative Site
-
-
Santander Department
-
Bucaramanga, Santander Department, Colombia, 680003
- Novartis Investigative Site
-
-
-
-
-
Cambridge, Det Forenede Kongerige, CB2 0QQ
- Novartis Investigative Site
-
-
-
-
-
Quezon, Filippinerne, 1102
- Novartis Investigative Site
-
-
National Capital Region
-
Makati City, National Capital Region, Filippinerne, 1218
- Novartis Investigative Site
-
-
-
-
California
-
San Bernardino, California, Forenede Stater, 92408
- Loma Linda University
-
-
Illinois
-
Hinsdale, Illinois, Forenede Stater, 60521
- Nep Assoc of Northern Illinois
-
-
-
-
-
Marseille, Frankrig, 13005
- Novartis Investigative Site
-
Nantes, Frankrig, 44093
- Novartis Investigative Site
-
-
-
-
Hong Kong
-
Hong Kong, Hong Kong, Hong Kong, 999077
- Novartis Investigative Site
-
-
-
-
Kerala
-
Kozhikode, Kerala, Indien, 673008
- Novartis Investigative Site
-
-
National Capital Territory of Delhi
-
New Delhi, National Capital Territory of Delhi, Indien, 110029
- Novartis Investigative Site
-
-
Telangana
-
Hyderabad, Telangana, Indien, 500082
- Novartis Investigative Site
-
-
-
-
-
Shenzhen, Kina, 518036
- Novartis Investigative Site
-
-
Guangxi
-
Nanning, Guangxi, Kina, 530022
- Novartis Investigative Site
-
-
Ningxia
-
Yinchuan, Ningxia, Kina, 750004
- Novartis Investigative Site
-
-
-
-
-
Selangor Darul Ehsan, Malaysia, 68100
- Novartis Investigative Site
-
-
Pahang
-
Kuantan, Pahang, Malaysia, 25100
- Novartis Investigative Site
-
-
Perak
-
Taiping, Perak, Malaysia, 34000
- Novartis Investigative Site
-
-
-
-
-
Aguascalientes, Mexico, 20230
- Novartis Investigative Site
-
Veracruz, Mexico, 91900
- Novartis Investigative Site
-
-
Tamaulipas
-
Tampico, Tamaulipas, Mexico, 89440
- Novartis Investigative Site
-
-
Yucatán
-
Mérida, Yucatán, Mexico, 97070
- Novartis Investigative Site
-
-
-
-
-
Coimbra, Portugal, 3004-561
- Novartis Investigative Site
-
-
-
-
Singapore
-
Singapore, Singapore, Singapore, 308433
- Novartis Investigative Site
-
-
-
-
Melikgazi
-
Kayseri, Melikgazi, Tyrkiet (Türkiye), 38039
- Novartis Investigative Site
-
-
Yenimahalle
-
Ankara, Yenimahalle, Tyrkiet (Türkiye), 06500
- Novartis Investigative Site
-
-
Yenisehir
-
Mersin, Yenisehir, Tyrkiet (Türkiye), 33110
- Novartis Investigative Site
-
-
-
-
-
Mainz, Tyskland, 55131
- Novartis Investigative Site
-
-
Lower Saxony
-
Braunschweig, Lower Saxony, Tyskland, 38126
- Novartis Investigative Site
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
Unequivocally positive ANA test result and/or a positive anti dsDNA at screening Active biopsy-proven lupus nephritis within 3 months of screening demonstrating Class III or IV lupus nephritis with or without co-existing features of Class V lupus nephritis.
Documentation of active renal disease at the time of screening necessitating the commencement of therapy with corticosteroids in combination with MMF/MPS.
eGFR ≥ 30 ml/min/1.73 m2 Vaccination against Neisseria meningitidis and Streptococcus pneumoniae infections Vaccination against Haemophilus influenzae infection Supportive care including stable dose regimen of anti-malarials (e.g. hydroxychloroquine) unless contraindicated, ACEi or ARB at either locally approved maximal daily dose or the maximally tolerated dose (per investigators' judgement) at screening, as per the local clinical practice. Doses should remain stable throughout the study.
First presentation or flare of lupus nephritis.
Exclusion Criteria:
Induction treatment with cyclophosphamide within 3 months of planned treatment for this study; treatment with calcineurin inhibitors within the previous 3 months prior to randomization.
Presence of rapidly progressive glomerulonephritis (RPGN) as defined by 50% decline in eGFR within 3 months prior to screening.
Renal biopsy presenting with interstitial fibrosis/tubular atrophy (IF/TA) or glomerulosclerosis of more than 50%, or which in the opinion of the investigator is such that it precludes likely response to immunosuppressive therapy.
Participants being treated with systemic corticosteroids (>5 mg/day prednisone or equivalent) for indications other than SLE or LN e.g. acute asthma, inflammatory bowel disease.
Participants being treated with systemic corticosteroids for SLE or LN will be excluded if they have taken more than an average of 15 mg/day prednisone (or equivalent) in the previous 4 weeks and more than an average of 30 mg/day in the previous 1 week Receipt of more than a total dose of 1000 mg equivalent i.v. pulse methylprednisolone (cumulative dose) within 2 weeks prior to enrollment (and at enrollment)
Other protocol-defined inclusion/exclusion criteria may apply
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Sekventiel tildeling
- Maskning: Firedobbelt
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Aktiv komparator: Iptacopan + standard of care (part 1)
Iptacopan + standard of care |
Taken for 52 Weeks
Andre navne:
|
|
Placebo komparator: Placebo matching iptacopan + standard of care (part 1)
Placebo matching iptacopan standard of care |
Taken for 52 Weeks |
|
Aktiv komparator: Iptacopan + standard of care (part 2)
Iptacopan + standard of care |
Taken for 52 Weeks
Andre navne:
|
|
Aktiv komparator: Iptacopan + placebo (part 2)
Iptacopan + placebo standard of care |
Taken for 52 Weeks
Andre navne:
|
|
Aktiv komparator: Placebo matching iptacopan + standard of care (part 2)
Placebo matching iptacopan + standard of care |
Taken for 52 Weeks |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Part 1 and 2: Proportion of patients achieving Complete Renal Response (CRR) at week 24 in the absence of renal flares
Tidsramme: Baseline and week 24
|
Part 1: To evaluate the proportion of patients achieving complete renal response with iptacopan treatment "A" plus standard of care, compared to treatment alone Part 2: To evaluate the proportion of patients achieving complete renal response with Iptacopan treatment "B" plus standard of care, compared to treatment "D" alone Part 2: To evaluate the proportion of patients achieving complete renal response with Iptacopan treatment "C" plus standard of care, compared to treatment "D" alone Complete Renal Response is defined as meeting the following criteria: estimated glomerular filtration rate (eGFR) ≥ 90 mL/min/1.73 m2 or no less than 85% of baseline value, and 24h urine protein-to-creatinine ratio (UPCR) ≤ 0.5 g/g. |
Baseline and week 24
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Parts 1 and 2: Proportion of patients achieving CRR or PRR in the absence of renal flares
Tidsramme: Baseline, week 24, week 52
|
Proportion of patients achieving complete renal response or partial renal response |
Baseline, week 24, week 52
|
|
Proportion of patients achieving ≥25% UPCR reduction in the absence of renal flares compared to baseline at week 24
Tidsramme: Baseline, week 24 week 52
|
Frequency of renal flares between weeks 24 and 52 |
Baseline, week 24 week 52
|
|
Log-transformed ratio to baseline of 24h UPCR at week 24
Tidsramme: Baseline week 24
|
Dose exposure response for reduction in proteinurea. (each 24h urine protein-to-creatinine ratio value will based on two 24 urine collections sampled within 10 days before the respective study visit) |
Baseline week 24
|
|
Change from baseline FACIT-Fatigue Score
Tidsramme: Weeks 24 and 52
|
Measure fatigue in patients |
Weeks 24 and 52
|
|
Change from baseline in SLEDAI-2K score at weeks 24 and 52
Tidsramme: Weeks 24 and 52
|
Measure disease activity in SLE |
Weeks 24 and 52
|
|
Change from baseline in BILAG-2004 score at weeks 24 and 52
Tidsramme: Weeks 24 and 52
|
Measure disease activity |
Weeks 24 and 52
|
|
Time-to-Complete Renal Response (CRR) based on first morning void(FMV) urine samples
Tidsramme: Week 24 and Week 52
|
Measurement of time to complete renal response based on urine samples |
Week 24 and Week 52
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Efterforskere
Efterforskere
- Studieleder: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Faktiske)
Primær færdiggørelse
Studieafslutning (Faktiske)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Urogenitale sygdomme
- Mandlige urogenitale sygdomme
- Nyresygdomme
- Urologiske sygdomme
- Urogenitale sygdomme hos kvinder
- Kvinders urogenitale sygdomme og graviditetskomplikationer
- Bindevævssygdomme
- Autoimmune sygdomme
- Sygdomme i immunsystemet
- Vandladningsforstyrrelser
- Urologiske manifestationer
- Glomerulonefritis
- Nefritis
- Patologiske tilstande, tegn og symptomer
- Hud- og bindevævssygdomme
- Tegn og symptomer
- Lupus erythematosus, systemisk
- Lupus nefritis
- Proteinuri
- Sundhedstjenester Administration
- Sundhedsvæsenets kvalitet, adgang og evaluering
- Sundhedskvalitet
- Kvalitetsindikatorer, sundhedsvæsenet
- Standard for pleje
- iptacopan
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- CLNP023K12201
- 2021-002046-33 (EudraCT nummer)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .